Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PORT-77 in Erythropoietic Protoporphyria and X-Linked Protoporphyria
NCT07820085Phase 3Recruiting
- Sponsor
- Portal Therapeutics
- Start
- Sep 2026
- Primary completion
- Mar 2029
- Countries
- 1
01
Overview
A Phase 3 trial of port-77 in erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), sponsored by Portal Therapeutics. Started Sep 2026; status: recruiting.
02
Drugs
port-77
03
Conditions
erythropoietic protoporphyria (EPP)X-linked protoporphyria (XLP)
Beyond the preview
Go deeper on NCT07820085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07820085.